1-哌啶羧酸,4-[4-[[(7-氰基-2-萘基)甲基](甲磺酰)氨基]苯氧基]-,1,1-二甲基乙基酯 | 179756-21-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-哌啶羧酸,4-[4-[[(7-氰基-2-萘基)甲基](甲磺酰)氨基]苯氧基]-,1,1-二甲基乙基酯
• 英文名称: N-{4-[(1-tert-butoxycarbonyl-4-piperidyl)oxy]phenyl}-N-[(7-cyano-2-naphthyl)methyl]methanesulfonamide
• 英文别名: N-[4-[(1-t-Butoxycarbonyl-4-piperidyl)oxy]phenyl]-N-[(7-cyano-2-naphthyl)methyl]methanesulfonamide；tert-butyl 4-[4-[(7-cyanonaphthalen-2-yl)methyl-methylsulfonylamino]phenoxy]piperidine-1-carboxylate
• CAS: 179756-21-9
• 化学式: C₂₉H₃₃N₃O₅S
• 分子量: 535.664
• InChiKey: BSQXOHVNBKSFTB-UHFFFAOYSA-N

物化性质

• 沸点：
  714.0±70.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  108
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-哌啶羧酸,4-[4-[[(7-氰基-2-萘基)甲基](甲磺酰)氨基]苯氧基]-,1,1-二甲基乙基酯 在 羟胺 、 乙酸酐 、 溶剂黄146 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 7-({Methanesulfonyl-[4-(piperidin-4-yloxy)-phenyl]-amino}-methyl)-naphthalene-2-carboxamidine
  参考文献：
  名称：

  Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors

  摘要：

  A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds I and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00927-7
• 作为产物：
  描述：

  4-(4-硝基苯氧基)四氢-1(2H)-吡啶羧酸叔丁酯 在 palladium on activated charcoal 吡啶 、 氢气 、 caesium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-哌啶羧酸,4-[4-[[(7-氰基-2-萘基)甲基](甲磺酰)氨基]苯氧基]-,1,1-二甲基乙基酯
  参考文献：
  名称：

  Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors

  摘要：

  A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds I and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00927-7

文献信息

• Amidinonaphthyl derivative or salt thereof
  申请人：Yamanouchi Pharmaceutical Co. Ltd

  公开号：US05869501A1

  公开（公告）日：1999-02-09

  An amidinonaphthyl derivative represented by the following general formula (I) which has coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. ##STR1## (symbols in the formula have the following meanings; R.sup.1 : a hydrogen atom or a group represented by the formula --A--W--R.sup.4, A: a group represented by the formula ##STR2## a group represented by the formula ##STR3## or a group represented by the formula --SO.sub.2 --, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula --NR.sup.5 --, R.sup.4 : a hydroxyl group, a lower alkoxy group, etc., R.sup.5 : a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R.sup.2 : a lower alkyl group, R.sup.3 : a hydrogen atom, a halogen atom, a carboxyl group, B: a lower alkylene group or a carbonyl group, and n: 0 or 1).

  以下为通式（I）表示的一种酰胺萘衍生物，具有凝血因子X抑制作用，可用作抗血栓剂等，其盐、中间体以及包含该酰胺萘衍生物的制药组合物。该酰胺萘衍生物通式（I）或其药学上可接受的盐。##STR1##（公式中符号的含义如下：R1：氢原子或由公式--A--W--R4表示的基团，A：由公式##STR2##表示的基团，由公式##STR3##表示的基团，或由公式--SO.sub.2--表示的基团，X：氧原子或硫原子，W：单键或由公式--NR5--表示的基团，R4：羟基、低碳基氧基等，R5：氢原子、氨基甲酰基、低碳基氧羰基等，R2：低碳基，R3：氢原子、卤原子、羧基，B：低碳基亚甲基或羰基，n：0或1）。
• NOVEL AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0798295A1

  公开（公告）日：1997-10-01

  An amidinonaphthyl derivative represented by the following general formula (I) which has a platelet aggregation inhibiting action based on the activated blood coagulation factor X inhibiting action and is useful as an anti-thrombus agent and the like, a salt thereof, an intermediate thereof and a pharmaceutical composition which comprises the amidinonaphthyl derivative. An amidinonaphthyl derivative represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. (symbols in the formula have the following meanings; R1: a hydrogen atom or a group represented by the formula -A-W-R4, A: a group represented by the formula a group represented by the formula or a group represented by the formula -SO2-, X: an oxygen atom or a sulfur atom, W: a single bond or a group represented by the formula -NR5-, R4: a hydroxyl group, a lower alkoxy group, etc., not a hydroxyl group or a lower alkoxy group, R5: a hydrogen atom, a carbamoyl group, a lower alkoxycarbonyl group, etc., R2: a lower alkyl group, R3: a hydrogen atom, a halogen atom, a carboxyl group, B: a lower alkylene group or a carbonyl group, and n: 0 or 1).

  一种由下式通式（I）表示的脒基萘衍生物、其盐、中间体和包含该脒基萘衍生物的药物组合物，该脒基萘衍生物具有基于活化血液凝固因子 X 抑制作用的血小板聚集抑制作用，可用作抗血栓剂等。 由以下通式（I）代表的脒基萘衍生物或其药学上可接受的盐。 (式中符号含义如下； R1：氢原子或由式-A-W-R4 所代表的基团、 A：由式 式所代表的基团 或由式 -SO2- 代表的基团、 X：氧原子或硫原子，W：单键或由式-NR5-代表的基团，R4：羟基、低级烷氧基等，不是羟基或低级烷氧基，R5：氢原子、氨基甲酰基、低级烷氧基羰基等，R2：低级烷基，R3：氢原子、卤素原子、羧基，B：低级亚烷基或羰基，n：0 或 1）。
• The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor
  作者：Fukushi Hirayama、Hiroyuki Koshio、Naoko Katayama、Hiroyuki Kurihara、Yuta Taniuchi、Kazuo Sato、Nami Hisamichi、Yumiko Sakai-Moritani、Tomihisa Kawasaki、Yuzo Matsumoto、Isao Yanagisawa

  DOI：10.1016/s0968-0896(01)00418-7

  日期：2002.5

  Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis, inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our investigation of a non-peptide, orally available FXa inhibitor, we found that a series of N-[(7-amidino-2-naphthyl)methyl]aniline derivatives possessed potent and selective inhibitory activities. Structure-activity relationship (SAR) of the substituent (R-1) on the central aniline moiety suggested that increasing lipophilicity caused a detrimental effect on anticoagulant activity (prothrombin time assay) in plasma. Several compounds bearing a hydrophilic substituent in R-1 showed not only potent FXa inhibitory activities but also high anticoagulant activities. The best compound in this series was sulfamoylacetic acid derivative 8o (YM-60828) which was a potent, selective and orally bioavailable FXa inhibitor and was chosen for clinical development. (C) 2002 Elsevier Science Ltd. All rights reserved.
• Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors
  作者：Wenrong Huang、Penglie Zhang、Jingmei F Zuckett、Lingyan Wang、John Woolfrey、Yonghong Song、Zhaozhong J Jia、Lane A Clizbe、Ting Su、Katherine Tran、Brian Huang、Paul Wong、Uma Sinha、Gary Park、Andrea Reed、John Malinowski、Stanley J Hollenbach、Robert M Scarborough、Bing-Yan Zhu

  DOI：10.1016/s0960-894x(02)00927-7

  日期：2003.2

  A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds I and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively. (C) 2002 Published by Elsevier Science Ltd.